Early onset of treatment effects with oral risperidone
- PMID: 17239237
- PMCID: PMC1781938
- DOI: 10.1186/1471-244X-7-4
Early onset of treatment effects with oral risperidone
Abstract
Background: The dogma of a delayed onset of antipsychotic treatment effects has been maintained over the past decades. However, recent studies have challenged this concept. We therefore performed an analysis of the onset of antipsychotic treatment effects in a sample of acutely decompensated patients with schizophrenia.
Methods: In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone. PANSS-ratings were obtained on day 0, day 1, day 3, day 7 and day 14.
Results: Significant effects of treatment were already present on day 1 and continued throughout the study. The PANSS positive subscore and the PANSS total score improved significantly more than the PANSS negative subscore.
Conclusion: Our results are consistent with the growing number of studies suggesting an early onset of antipsychotic treatment effects. However, non-pharmacological effects of treatment also need to be taken into consideration.
Similar articles
-
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020. Clin Ther. 2008. PMID: 19167596
-
[Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].Encephale. 2007 Dec;33(6):973-81. doi: 10.1016/j.encep.2006.07.003. Epub 2007 Sep 4. Encephale. 2007. PMID: 18789790 Clinical Trial. French.
-
An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.Kathmandu Univ Med J (KUMJ). 2006 Apr-Jun;4(2):152-60. Kathmandu Univ Med J (KUMJ). 2006. PMID: 18603890 Clinical Trial.
-
Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.Expert Rev Neurother. 2009 Jan;9(1):9-31. doi: 10.1586/14737175.9.1.9. Expert Rev Neurother. 2009. PMID: 19102665 Review.
-
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Clin Ther. 2008. PMID: 18840365 Review.
Cited by
-
Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment.Pharmacol Biochem Behav. 2011 Jun;98(4):559-69. doi: 10.1016/j.pbb.2011.03.007. Epub 2011 Mar 21. Pharmacol Biochem Behav. 2011. PMID: 21402097 Free PMC article.
-
Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine.Psychopharmacology (Berl). 2013 May;227(1):67-78. doi: 10.1007/s00213-012-2939-y. Epub 2013 Jan 15. Psychopharmacology (Berl). 2013. PMID: 23318695 Free PMC article.
-
Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion.Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):175-82. doi: 10.1016/j.pnpbp.2012.03.007. Epub 2012 Mar 26. Prog Neuropsychopharmacol Biol Psychiatry. 2012. PMID: 22476004 Free PMC article.
-
Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine.Behav Pharmacol. 2012 Feb;23(1):66-79. doi: 10.1097/FBP.0b013e32834ecac4. Behav Pharmacol. 2012. PMID: 22157143 Free PMC article.
-
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.Neuropsychopharmacology. 2012 Jan;37(1):16-42. doi: 10.1038/npp.2011.199. Epub 2011 Sep 28. Neuropsychopharmacology. 2012. PMID: 21956443 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous